SEC Comment Letter for NextCure, Inc. (NXTC) (CIK 0001661059) (NXTC) — Apr 29, 2021

NextCure, Inc. (NXTC) (CIK 0001661059)
Date: April 29, 2021 · CIK: 0001661059 · Accession: 0000000000-21-005475

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-38905

Date

April 29, 2021

Author

Steven Cobourn

Form

UPLOAD

Company

NextCure, Inc. (NXTC) (CIK 0001661059)

Letter

United States securities and exchange commission logo April 29, 2021 Steven Cobourn Chief Financial Officer NextCure, Inc. 9000 Virginia Manor Road, Suite 200 Beltsville, MD 20705 Re:NextCure, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed March 4, 2021 File No. 001-38905 Dear Mr. Cobourn: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
April 29, 2021
Steven Cobourn
Chief Financial Officer
NextCure, Inc.
9000 Virginia Manor Road, Suite 200
Beltsville, MD 20705
Re:NextCure, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2020
Filed March 4, 2021
File No. 001-38905
Dear Mr. Cobourn:
            We have completed our review of your filings.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io